The dataset connects claims, labs and EHR, including physician notes to analyse: Who meets drug label or payer criteria based on actual BMI and comorbidities How titration and dosing progress in real-world care What metabolic outcomes patients achieve over time Which safety signals, such as liver or renal changes, emerge across populations Why patients discontinue or switch treatments, as documented in notes See real-world GLP-1 evidence in action Register for our webinar where we dive deeper into GLP-1 real-world evidence
W., Im, G
MT-2 activates two distinct melanocortin receptor subtypes MC1R and MC4R producing effects that span skin pigmentation, sexual function, appetite regulation, body composition, and neuroprotection
Medical Safety Considerations for Dose Reduction Semaglutide is a glucagon-like peptide-1 receptor agonist designed to work optimally within specific dose ranges
J.ChoJ.-H.KimJ.-W.et al (2020)
The available data suggest an incidence rate of 0.02%3.23%.[] The typical picture of NMS is characterized by fever, rigidity, altered sensorium, and autonomic disturbances.[] Various risk factors have been identified for the development of NMS [Table 7]